-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $5.5

Benzinga·12/03/2025 11:47:16
语音播报
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $6.5 to $5.5.